Figure 3 | Scientific Reports

Figure 3

From: Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9

Figure 3

Group comparison of pro-fibrotic markers between 24 healthy control subjects, and all participants’ maximum plasma levels during hospital stay and at the 3-months follow-up evaluation, performed with Mann–Whitney U test and Wilcoxon paired test. Controls, 24 healthy control subjects. Maximum, maximum plasma levels during the hospital stay. 3 months, plasma levels at the 3-month follow-up. MMP-9 matrix metalloproteinase 9, TIMP-2 tissue inhibitor of metalloproteinases 2, SP-D surfactant protein D, VEGF-A vascular endothelial growth factor. Median MMP-9 level healthy control subjects: 2.70 ng/mL, median maximum level MMP-9: 3.83 ng/mL, median MMP-9 level at 3 months: 2.93 ng/mL. Median TIMP-2 level healthy control subjects: 7.78 ng/mL, median maximum level TIMP-2: 7.85 ng/mL, median TIMP-2 level at 3 months: 8.76 ng/mL. Median SP-D level healthy control subjects: 20.9 ng/mL, median maximum level SP-D 16.4, median SP-D level at 3 months: 14.1 ng/mL. Median VEGF-A level healthy control subjects: 125 pg/mL, median maximum VEGF-A level: 277 pg/mL, median VEGF-A level at 3 months: 216 pg/mL. *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page